-
Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer
•
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase III VERITAC-2 study. The trial assessed vepdegestrant alone versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer who experienced disease progression following prior…
-
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
•
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly & Co. (NYSE: LLY). The alliance aims to discover, develop, and commercialize molecular glue therapeutics in oncology. Collaboration DetailsSpecifically, Magnet’s TrueGlue discovery platform will be utilized to identify molecular glues capable of inducing…
-
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
•
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015, a molecular glue product, for clinical studies in hematological and solid tumors with RAS mutations. The approval follows positive preclinical data and a strategic licensing deal with U.S.-based Erasca, Inc. Drug ProfileJYP0015, a novel pan-RAS…
-
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
•
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a licensing agreement with U.S.-based Photys Therapeutics, Inc. for its HPB-143, a targeted protein degrader (TPD) targeting IRAK4. Under the agreement, Photys will obtain exclusive global development, manufacturing, and commercialization rights to the drug, excluding Greater…
-
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
•
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and Drug Administration (FDA) has granted clinical clearance for DEG6498, its molecular glue degrader (MGD) targeting human antigen R (HuR). The drug will enter early-stage trials to assess its safety and efficacy in solid tumors. Drug…
-
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with Neomorph, Inc., aimed at developing novel molecular glue degraders for multiple targets across oncology and immunology. The partnership seeks to leverage Neomorph’s innovative technology to address critical needs in cancer and immune-related diseases. Molecular Glue…
-
Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I clinical study for its Category 1 chemical drug, HDM2006, in patients with advanced solid tumors. This marks a significant step forward in…
-
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
•
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology specialist LEO Pharma A/S. The partnership aims to bolster the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs, targeting the potential treatment of patients with…
-
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
•
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), has entered into a global license deal with US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ). The partnership aims to develop potential best-in-class BTK degraders for the treatment of…
-
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
•
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its drug candidate, HP568. The Chinese firm plans to test HP568 in patients with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative…
-
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
•
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open, multi-center Phase II study assessing the safety, pharmacokinetics, and anti-tumor activity of its Category 1 chemical drug, HP518, in patients with metastatic castration resistant prostate cancer (mCRPC). Innovative Mechanism of Action for HP518HP518 is an…
-
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
•
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful completion of its Series A financing round, raising RMB100 million (USD 13.81 million). The round was led by Beijing Longpan Venture Capital Centre, with additional support from Tian Rui Feng Nian Investment and Shanghai Zhangke…
-
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
•
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is poised to merge with US-based Pulmatrix, Inc. (NASDAQ: PULM). The merger will result in a Nasdaq-listed entity focused on advancing targeted protein degradation technology, a promising field in drug development. Cullgen’s uSMITE Technology PlatformCullgen leverages…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for a suite of drugs including HRS-2189, HRS-5041, HRS-1358, HRS-8080, SHR-8068, adebrelimab, and HRS-6209. The company is set to initiate an open, multi-center Phase…
-
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
•
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical company Novartis (NYSE: NVS), granting Novartis exclusive global development and commercialization rights to Monte Rosa’s VAV1-targeted molecular glue degraders (MGDs), including the investigational drug MRT-6160. As per the agreement, Novartis will make an upfront payment…
-
Huadong Medicine Gets Green Light for HPK1 PROTAC Drug HDM2006 in Advanced Solid Tumors
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has received approval from China’s National Medical Products Administration (NMPA) to conduct a study for its Category 1 chemical drug HDM2006, which targets advanced solid tumors. This development marks a significant step for Huadong as it…
-
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
•
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and licensing agreement with Massachusetts-based biotech firm TRIANA Biomedicines. The collaboration aims to develop innovative molecular glue degraders targeting a variety of diseases, with a focus on oncology, according to a press release from TRIANA. Under…
-
Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
•
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its drug candidate HP568. This new drug is intended for the treatment of estrogen receptor (ER) positive, human epidermal…
-
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
•
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton’s tyrosine kinase (BTK) degrader program. According to…
-
BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its novel compound BGB-16673. This investigational Bruton’s tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC), known as a proteolysis-targeting chimera (PROTAC) product, represents…
